Bio Pharma Dive
SEPTEMBER 12, 2023
The two-year-old San Diego biotech is allied with The Jackson Laboratory to engineer better mouse models of the rare diseases it plans to target.
Pharma Times
JANUARY 7, 2022
The platform integrates primary human tissue samples into early target and drug discovery research.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
JULY 22, 2022
Sangamo Therapeutics has received orphan medicinal product designation (OMPD) from the European Commission (EC) for its Investigational autologous Chimeric Antigen Receptor Regulatory T Cell (CAR-Treg) cell therapy, TX200, for solid organ transplantation.
Pharmaceutical Technology
MAY 10, 2023
SYNB1934 consumes Phe in the gastrointestinal (GI) tract by leveraging genetic engineering of the drug or drug-carrying capsule, probiotic escherichia coli (E coli) Nissle. SYNB1934 has also gained rare paediatric disease designation (RPDD) from the FDA and orphan drug designation from the European Medicines Agency (EMA).
Scienmag
APRIL 27, 2022
Researchers at the University of Massachusetts Amherst recently announced that they have engineered a new class of material, called a “polyzwitterionic complex,” or “pZC,” which is able to both withstand the harsh acidic conditions of the stomach and then dissolve predictably in the comparatively gentle environment of the small intestine.
STAT News
FEBRUARY 9, 2023
But a small new study suggests that help might come from an engineered virus. The subtype is considered particularly dangerous, as it tends to grow and spread more aggressively than other types, and it has fewer effective treatment options.
Pharmaceutical Technology
APRIL 13, 2023
Clinical-stage biopharmaceutical firm Alentis Therapeutics has raised $105m in a Series C financing round for advancing transformational medicines targeting the CLAUDIN-1 protein. ALE.F02 is being developed for the treatment of advanced kidney, lung and liver fibrosis while ALE.C04 is a potential treatment to target CLDN1-positive tumours.
Expert insights. Personalized for you.
269 
Let's personalize your content